Bio-Rad launches GBS positive, negative run controls
June 11, 2024—Bio-Rad Laboratories has launched its Exact Diagnostics GBS positive and negative run controls.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Liaison Plex Yeast Blood Culture assay gets 510(k) clearance
June 7, 2024—Diasorin announced it has received 510(k) clearance from the FDA for the company’s Liaison Plex Yeast Blood Culture assay, the second molecular multiplexing panel on the Liaison Plex.
FDA clears Horiba Yumizen H2500 hematology analyzer
June 6, 2024—Horiba has announced that its high-throughput Yumizen H2500 hematology analyzer has received FDA 510(k) clearance and is available for sale in the United States.
Epredia SlideMate Laser gets MedTech Breakthrough Award
June 3, 2024—MedTech Breakthrough announced that Epredia has been selected as the winner of best new technology solution—pathology for its SlideMate Laser printer in the 8th annual MedTech Breakthrough Awards program.
ACLA challenges FDA final rule to regulate LDTs
May 29, 2024—The American Clinical Laboratory Association and its member company, HealthTrackRx, filed a lawsuit today against the U.S. Food and Drug Administration in the U.S. District Court for the Eastern District of Texas, challenging the agency’s May 6 final rule, which seeks to regulate professional laboratory testing services as medical devices under the Federal Food, Drug, and Cosmetic Act.
FDA clears BioMérieux Vidas TBI test
May 28, 2024—BioMérieux received FDA 510(k) clearance for its Vidas TBI (GFAP, UCH-L1), a serum-based test that supports the assessment of patients with mild traumatic brain injury, including concussion.
Roche gets breakthrough device designation for Lp(a) assay
May 22, 2024—Roche announced that the Tina-quant lipoprotein Lp(a) RxDx assay, developed in collaboration with Amgen, has received breakthrough device designation from the FDA.
FDA approves Imdelltra for extensive-stage SCLC
May 20, 2024—Amgen announced FDA approval of Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
NxTag respiratory panel v2 gets FDA clearance
May 17, 2024—Diasorin received FDA 510(k) clearance for its NxTag Respiratory Pathogen Panel v2.
BD Onclarity HPV assay approved for self-collected samples
May 16, 2024—BD announced FDA approval of the BD Onclarity HPV assay for the use of self-collected vaginal specimens for HPV testing when cervical specimens cannot otherwise be obtained.